Organization
OX2 Therapeutics
2 clinical trials
Clinical trial
Phase I Trial: CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy With Adjuvant Reirradiation for Recurrent High-Grade Glioma and Newly Diagnosed Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma in Children and Young AdultsStatus: Recruiting, Estimated PCD: 2025-09-15
Clinical trial
Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent GlioblastomaStatus: Active (not recruiting), Estimated PCD: 2023-11-01